NasdaqGM:LGNDPharmaceuticals
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?
Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it.
The stock is up 97.4% over the past year and 175.9% over three years, even though it has fallen 5.7% over the last week and 10.3% over the past month. It has gained 9.4% so far this year.
Recent headlines have focused on Ligand Pharmaceuticals as a platform business in the wider pharmaceuticals and biotech space, with attention on how its...